Skip to main content

Table 1 Clinical characteristics of patients and controls

From: Endotoxin- and ATP-neutralizing activity of alkaline phosphatase as a strategy to limit neuroinflammation

  (number = 18) (number = 26) (number = 11)
Age at onset (SD) NA 37 (12) NA
Age at sampling (SD; range) 37 (12; 21 to 59) Total MS: 41 (12; 19 to 59) 39 (13; 20 to 57)
   RR-MS: 34 (11; 19 to 59)  
   PP-MS: 46 (9; 31 to 58)  
Female (%) 78 73 45
Disease duration, years (SD) NA 3 (1)a NA
Presenting symptoms (number)    
Optic nerve   2  
Spinal cord NA 16 NA
Brainstem/cerebellum   3  
Cerebrum   5  
Raised IgG-index or oligoclonal bands (number) NA 18/23 NA
  1. aAt sampling, five patients were still clinically isolated syndrome (CIS) patients. Of these patients, four developed RR-MS after sampling. One CIS patient was at high risk for developing MS (fulfilment of the Barkhof criteria on MRI and oligoclonal bands and raised IgG-index in the CSF) and was followed for seven years without new neurological complaints. CSF, cerebrospinal fluid; HC, healthy controls; IgG, immunoglobulin G; MRI, magnetic resonance imaging; MS, multiple sclerosis; OND, other neurological disease; PP-MS, primary progressive MS; RR-MS, relapsing-remitting MS; SD, standard deviation.